First Survival Results With Immunotherapy, TNBC – Medscape
TIME |
First Survival Results With Immunotherapy, TNBC
Medscape WASHINGTON, DC — The proportion of patients with metastatic triple-negative breast cancer who respond to the immunotherapy atezolizumab (Tecentriq, Genentech) is only 10% to 13%, but the responses tend to last a long time, according to new results … Triple-negative Breast Cancer Patients Who Responded to Immunotherapy Had Long-term Survival BenefitMilTech Atezolizumab Yields Long-Term OS in mTNBC SubsetOncLive |
|
CRISPR-Cas9 Epigenome Editing Screen Reveals Regulatory Elements
GenomeWeb NEW YORK (GenomeWeb) – Researchers interested in untangling the functional roles of regulatory elements have a new screening tool at their disposal: a CRISPR-Cas9-based epigenomic editing scheme. In a study appearing online today in Nature … |
|
#AACR17: Study Explores Best Time to Give CAR T Cell Therapy
Memorial Sloan Kettering Cancer Center (blog) For patients with leukemia who relapse after chemotherapy, treatment options have traditionally been limited. At MSK, an experimental immunotherapy called CAR T therapy has expanded options for these patients. New research data presented at this year’s … |
TIME |
Immunotherapy May Treat This Deadly Breast Cancer
TIME But in a new presentation at the annual American Association for Cancer Research meeting, researchers say that one of the latest immunotherapy drugs called atezolizumab, or Tecentriq, may help people with triple negative breast cancer to live longer. First Survival Results With Immunotherapy, TNBCMedscape Breast Cancer ‘Immunotherapy‘ Helps Some With Tough-to-Treat DiseaseArizona Daily Star Triple-negative Breast Cancer Patients Who Responded to Immunotherapy Had Long-term Survival BenefitMilTech OncLive all 16 news articles » |
Worldcrunch |
The Shady Business Of Experimental Stem Cell Treatments
Worldcrunch And yet patients often receive invitations from private clinics or doctors promising a miracle cure using stem cells, which can be multiplied in specialized settings or surfaces. “Patients are ready to enter into any protocol or clinical trial rather … |